A 14-week, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of pregabalin (150mg-600mg/day) using a flexible optimal dose schedule in patients with painful diabetic peripheral neuropathy (DPN)
Latest Information Update: 27 Jan 2021
At a glance
- Drugs Pregabalin (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer; Viatris Inc
- 11 Sep 2018 Results assessing 12- to 13-week responder outcomes in patients with pDPN treated with pregabalin in 6 trials (Study 1008-149, Study 1008-155, NCT00156078, NCT00159679, NCT00143156 and NCT00553475; n=939) published in the Advances in Therapy
- 30 Aug 2006 Status change
- 18 Dec 2005 New trial record.